Patient-derived xenograft or PDX model is now recognized as the good in vivo model for predicting clinical outcomes. It is derived by growing a fragment of patient tumor tissue on immuno-deficient mice, which faithfully recapitulates the genomic, phenotypic and molecular biological complexities found in the cancer tissue of origin.